Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (8,376,002)	$ (7,654,575)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	1,177,702	1,030,415
Depreciation and amortization	77,028	1,495
Changes in operating assets and liabilities:
Receivable due from collaboration agreement	(147,880)
Research and development tax incentive receivable	(108,097)
Prepaid assets and other current assets	237,646	534,612
Accounts payable	192,211	521,114
Accrued compensation	(416,910)
Deferred revenue	118,000	(24,315)
Net cash used in operating activities	(7,246,302)	(5,591,254)
Cash flows from investing activities:
Purchases of property and equipment	(137,231)	(476,128)
Net cash used in investing activities	(137,231)	(476,128)
Cash flows from financing activities:
Net proceeds from issuance of common stock		28,023,564
Proceeds from issuance of common stock for stock option exercises		655,253
Proceeds from issuance of common stock for warrant exercises		180,212
Net cash provided by financing activities		28,859,029
Effect of exchange rate changes on cash and cash equivalents	3,031	(37,330)
Net change in cash and cash equivalents	(7,380,502)	22,754,317
Cash and cash equivalents at beginning of period	33,794,672	35,300,805
Cash and cash equivalents at end of period	26,414,170	58,055,122
Supplemental disclosure of non-cash investing and financing activities:
Purchases of equipment included in accounts payable	338,674
Cashless exercise of warrants		$ 416